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Beta-antagonistAbstract Background: The ﬁeld of cochlear implantation has been expanding rapidly and it has
been hailed as one of the greatest advances in otology. The technique of anesthesia plays a crucial
role in success of cochlear implant surgery as the anesthesiologist has to produce conditions which
facilitate surgery by inducing bloodless operative ﬁeld.
Study objective: To determine the efﬁcacy of dexmedetomidine versus esmolol usage as an adjunct
to induce controlled hypotension in children undergoing cochlear implant surgery.
Design: Clinical trial study.
Setting: Operating room in a university hospital.
Patients: 70 children aged 2–4 years scheduled for cochlear implant surgery under general anesthe-
sia. Patients were randomly allocated according to drugs used into two equal groups (35 patients in
each group). Interventions: Group (D): The patients in this group received a bolus dose of
dexmedetomidine 0.5 ug/kg over 10 min followed by continuous infusion 0.2–0.5 ug/kg/h after
induction of anesthesia but before surgery. Group (E): The patients in this group received a bolus
dose of esmolol 0.5 mg/kg over 10 min followed by continuous infusion 100–300 ug/kg/min after
induction of anesthesia but before surgery.
Measurements: Heart rate, Mean Arterial blood Pressure, Quality of surgical ﬁeld, operative time,
adverse events.
Main results: The quality of surgical ﬁeld was comparable between both groups in all times of mea-
surements. The time to ﬁrst analgesic request was statistically signiﬁcant longer in group (D) than in
group (E) and the total tramadol consumption was statistically signiﬁcant less in group (D) than in
group (E).
Conclusions: In our study both dexmedetomidine and esmolol were effective in reducing MABP,
and lowering the heart rate providing dry surgical ﬁeld and ensured good surgical condition during
cochlear implant surgery in pediatric patients.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The ﬁeld of cochlear implantation has been expanding rapidly
and now it is an acceptable therapeutic option for those
patients with irreversible hearing loss and deaf mutism. It
has been hailed as one of the greatest advances in otology [1].
The anesthesiologist is an integral member of the cochlear
implant team whose anesthetic as well as communication skills
are put to test. The technique of anesthesia plays a crucial role
in success of cochlear implant surgery as the anesthesiologist
has to produce conditions which facilitate surgery by inducing
bloodless operative ﬁeld, use of nerve stimulators and treat
post-operative complications such as nausea, vomiting and
vertigo [2].
A bloodless surgical ﬁeld is ideal for cochlear implant sur-
gery, as even small amounts of blood will obscure the sur-
geon’s view in microsurgery. A combination of physical and
pharmacologic techniques is used to minimize bleeding [3].
Controlled hypotension is commonly used to achieve a
bloodless operative ﬁeld. Although the primary premise for
its use is to limit intraoperative blood loss, an additional ben-
eﬁt is improved visualization of the surgical ﬁeld [4].
The use of controlled hypotension in pediatric surgery was
ﬁrst reported in 1953, thereafter, widely used in various pedi-
atric surgical procedures, including scoliosis surgery, vascular
surgery, and neurosurgery [5].
In older children (9–18 years) undergoing functional endo-
scopic sinus surgery under controlled hypotension, no adverse
outcomes were noted, and safe reduction in blood pressure
(BP) has been regarded as a maximum of 25% below baseline
mean BP [6].
Various drugs have been used to induce controlled hypoten-
sion including vasodilators, alpha- and beta-adrenergic
antagonist, beta-adrenergic antagonists, and high doses of
potent inhaled anesthetics [7].
While hypotension has proved safe to use in children, some
develop tachycardia that delays the onset of hypotension. The
introduction of the short acting beta-blocker esmolol enabled
more precise control of heart rate.
Esmolol is an ultra-short acting intravenous cardio selective
beta-antagonist. It has an extremely short elimination half-life
and a total body clearance approaching 3 times of cardiac out-
put and 14 times of hepatic blood ﬂow [8].
Dexmedetomidine is a speciﬁc and selective a2-adrenoceptor
agonist. Drugs acting as agonists at a2-adrenoceptors may
enhance anesthesia by providing dose-related sedation, anxiol-
ysis, decreased upper airway secretions, perioperative hemody-
namic stability and analgesia. There is substantial evidence that
the a2-agonists also exert an anesthetic-sparing effect [9].
The aim of this study was to determine the efﬁcacy
ofdexmedetomidine versus esmolol usage as an adjunct to
induce controlled hypotension in children undergoing cochlear
implant surgery. The primary outcomes are the quality of sur-
gical ﬁeld and surgical area bleeding score while duration of
surgery and time to ﬁrst analgesic request are the secondary
outcomes.
2. Patients and methods
This randomized prospective double-blind study was con-
ducted on 70 children aged 2–4 years scheduled for cochlearimplant surgery under general anesthesia in the otorhinolaryn-
gology department, Tanta University Hospital, after approval
of the ethics committee and obtaining written informed con-
sent from parents of each patient.
The approval code of ethics committee was 30290/05/15.
The randomization was performed using sealed numbered
envelopes indicating the group of each patient. A blind nurse
who did not participate in patients’ follow-up read the number
and made group assignments. Study drugs were prepared by
an independent anesthesiologist.
All patients’ data were conﬁdential with secret codes and
were used for the current study only.
Any unexpected risk appears during the course of the study
was cleared to the guardian of the patient and the ethical com-
mittee on time and the proper measures were taken to mini-
mize or overcome these risks.
2.1. Inclusion criteria
Pediatric patients aging 2–4 years of either sex with ASA I and
II scheduled for cochlear implant surgery.
2.2. Exclusion criteria
Refusal to share in the study, known allergy to any of the
study drugs, diabetes, liver and/or kidney disease, congenital
heart disease and hemodynamic instability (Fig. 1).
2.3. Preoperative preparation
All patients were underwent preoperative assessment by his-
tory taking, physical examination and laboratory investiga-
tions as needed.
2.4. Intraoperative management
General anesthesia was induced by sevoﬂurane (7 vol.%,).
After the patients’ loss of consciousness, intravenous line
was inserted. Orotracheal intubation was facilitated by 1 lg/
kg fentanyl and cisatracurium 0.15 mg/Kg and conﬁrmed by
clinical observation of chest wall movement, auscultation of
chest and presence of square wave of capnogram. The patients
were connected to mechanical ventilation. The respiratory rate
and tidal volume were adjusted to maintain an ETCO2
between 32 and 35 mmHg.
Arterial catheter was inserted in the radial artery after
Allen’s test for measurement of invasive blood pressure. Folly
catheter was used to decompress the urinary bladder and to
monitor urine output.
Anesthesia was maintained with sevoﬂurane 2–3 vol.% in
100 O2 and top up dose of cisatracurium 0.02 mg/kg every
30 min. Standard patient monitoring (electrocardiogram,
non-invasive arterial pressure, heart rate, pulse oximetry, and
end-tidal CO2) was used during anesthesia. All patients
received a 5% dextrose in 0.45% saline at rate 5 ml/kg/h.
Facial nerve was identiﬁed intraoperatively by electrical
stimulation after the effect of muscle relaxant has adequately
reversed as evidenced by the nerve stimulator (train of four
response); anesthesia was maintained during this stage by
bolus dose of propofol 0.5 mg/kg and after the test was done
muscle relaxant was given till the end of surgery.
Lost for follow up (0)
Assessed for eligibility(90)
Enrollment
Randomized (70)
Excluded (20)
Not meeng criteria (12)
Parents refusal (8)
Allocated to intervenon(35)
Received Allocated to intervenon(35)
Did not Receive Allocated to intervenon (0)
Lost for follow up (0)
Analyzed (35)
Excluded from analysis (0)
Analyzed (35)
Excluded from analysis (0)
Allocated to intervenon(35)
Received Allocated to intervenon(35)
Did not Receive Allocated to intervenon (0)
Allocaon
Follow up
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Figure 1 Patient ﬂow diagram.
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stopped and muscle relaxant was reversed with atropine and
neostigmine and the patient allowed to breathe spontaneously.
The ETT was removed in deep plane of anesthesia to prevent
coughing, bucking and sudden agitation which can displace the
implant and the children were kept in recovery position and
were transferred to postanesthesia care unit.
Metoclopramide 0.15 mg/kg and dexamethasone 0.15 mg/kg
were administered for prophylaxis of postoperative nausea
and vomiting (PONV) before the end of surgery. Ondansetron
0.1 mg/kg was administered for treatment of PONV.
2.5. Randomization
The randomization was performed using sealed numbered
envelopes indicating the group of each patient. A blind nurse
who did not participate in patients’ follow-up read the number
and made group assignments. Study drugs were prepared by
an independent anesthesiologist.
The process of inclusion in the study went on until the
required number of patients was reached. All operating room
anesthesiologists, surgeons, and nurses were blinded to ran-
domization, and preparations.
Patients were randomly allocated according to drugs used
into two equal groups (35 patients in each group):
Group (D): The patients in this group received a bolus dose
of dexmedetomidine (Precedex, Meditera, 200 lg/2 mL)
0.5 ug/kg over 10 min followed by continuous infusion
0.2–0.5 ug/kg/h after induction of anesthesia but before
surgery, in order to maintain the mean arterial blood pres-
sure within 20–25% less than baseline reading.Group (E): The patients in this group received a bolus
dose of esmolol (Brevibloc, Eczacibasi, 100 mg/10 mL)
0.5 mg/kg over 10 min followed by continuous infusion
100–300 ug/kg/min after induction of anesthesia but
before surgery, in order to maintain the mean arterial
blood pressure within 20–25% less than baseline reading.
The infusions of study drugs were terminated 10 min prior
to end of surgery to allow rise in blood pressure for effec-
tive hemostasis.
Measurements
 Demographic data: age, sex, ASA classiﬁcation.
 Heart rate, Mean Arterial blood Pressure (preoperatively,
after induction, then every 10 min).
 Quality of surgical ﬁeld (by the operating surgeon every
30 min): with a predeﬁned scale adapted from that of Dol-
man et al. [10].1 = minimal bleeding: not a surgical nuisance
2 = mild bleeding: but does not affect dissection
3 = moderate bleeding: slightly compromises dissection
4 = severe bleeding: signiﬁcantly compromises
dissection
5 = massive bleeding: prevent dissection
 Operative time.
 Any adverse events.
 Postoperative analgesia according to FLACC score [11].
The pain intensity was assisted by a person who was blind
to study by using FLACC scale [11] Table 1 graded from 0 to
10 (0 = no pain, 10 = the worst possible pain) in the following
time 2 h, 4 h, 6 h, 8 h, 12 h, and 18 h after recovery.
Table 1 FLACC scale.
Criteria Score 0 Score 1 Score 2
Face No
particular
expression
or smile
Occasional
grimace or frown,
withdrawn,
uninterested
Frequent to
constant
quivering chin,
clenched jaw
Legs Normal
position or
relaxed
Uneasy, restless,
tense
Kicking, or
legs drawn up
Activity Lying
quietly,
normal
position,
moves easily
Squirming,
shifting back and
forth, tense
Arched, rigid
or jerking
Cry No cry
(awake or
asleep)
Moans or
whimpers;
occasional
complaint
Crying
steadily,
screams or
sobs, frequent
complaints
Consolability Content,
relaxed
Reassured by
occasional
touching, hugging
or being talked
to, distractible
Diﬃcult to
console or
comfort
The Face, Legs, Activity, Cry, Consolability scale or FLACC scale
is a measurement used to assess pain for children between the ages
of 2 months–7y or individuals that are unable to communicate their
pain. The scale is scored between a range of 0–10 with 0 repre-
senting no pain while 10 representing the worst pain. The scale has
5 criteria each assigned a score of 0, 1 or 2.
Table 2 Demographic data; duration of surgery, tramadol
consumption; time of ﬁrst analgesic requirement.
Variables Group (D)
N= 35
Group (E)
N= 35
P
value
Age (yr) 2.3 ± 1.08 2.8 ± 1.24 0.15
Weight (kg) 14.4 ± 1.93 12.10 ± 1.71 0.68
Sex (M/F) 19/16 20/15
Duration of surgery (min) 90.65 ± 6.16 92.75 ± 6.58 0.71
Tramadol consumption
(mg)
10.45
± 10.05
18.25
± 11.57
0.01
Time to ﬁrst analgesic
request (h)
8.95 ± 2.06 4.85 ± 1.87 0.02
Table 4 Quality of surgical ﬁeld.
Predeﬁned scale Group D N= 35 Group E N= 35 P
0 0 0
1 20 18 0.7
2 13 15 0.4
3 2 2 0.6
4 0 0
5 0 0
Table 3 The value of pain score.
Time (h) Group D N= 35 Group E N= 35 P1
2 1.05 ± 0.8 1.03 ± 0.85 0.573
4 1.37 ± 1.85 3.17 ± 0.59 0.0.03
6 2.2.±0.80 4.0.13 + 0.68 0.01
8 4.30 ± 0.27 5.90 ± 0.79 0.01
12 5.4000 ± 0.84 5.85 ± 1.075 0.6
18 4.45 ± 0.90 4.30 ± 0.65 0.1
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on pain score. If the value was less than 5, rectal paracetamol
20 mg/kg was given, if the value was more than 5, tramadol
1 mg/kg was given intravenously and recorded. The time to
ﬁrst dose of analgesia and total amount of tramadol used were
recorded in all patients. Postoperative complications such as
nausea, vomiting or bleeding were recorded.
Patients were discharged postoperatively when they had no
or mild pain (FLACC< 3), were able to tolerate clear ﬂuids
and soft food and had no bleeding or nausea or vomiting.
2.6. Statistical analysis
The sample size was calculated using the following assump-
tion: the surgical area bleeding score was the main response
variable, and medcalc program version 3.5 was used for sam-
ple size calculation.
Power analysis identiﬁed 32 patients per group, required to
detect 15% difference between groups with a power 80% and a
signiﬁcant level of 0.05. However, to enable detection of poten-
tial variations between the two groups and avoid potential
errors, 35 patients were included in each group.
Comparison of demographic data and time of surgery was
done by Student’s t-test. Two way analysis of variance with
correction for repeated measurements was used for heart rate
and blood pressure comparison. Mann–Whitney U test was
used for nonparametric measurements including quality of
surgical ﬁeld and pain score. P< 0.05 was considered
signiﬁcant.3. Results
This study was carried out on 70 patients divided into two
groups, 35 in each group. The groups were comparable with
regard to demographic data including age, weight, and dura-
tion of surgery. The Time to ﬁrst analgesic request was statis-
tically signiﬁcant longer in group (D) than in group (E) and the
total tramadol consumption was statistically signiﬁcant less in
group (D) than in group (E) [Table 2].
Pain score after 2 h was statistically insigniﬁcant between
both groups (P> 0.05), while pain score at 4 h, 6 h, and 8 h
in group D was signiﬁcantly less when compared to group E
(P< 0.05) Table 3.
Pain score at 12 h and 18 h was comparable between both
groups p> 0.05 (Table 3).
The quality of surgical ﬁeld was comparable between both
groups in all times of measurements p> 0.05 Table 4.
The MABP and HR were comparable between both groups
in all times of measurements, p value > 0.05 and the values in
both groups were decreased signiﬁcantly after infusion of the
study drugs till the end of surgery when compared to baseline
Tables 5 and 6.
Table 5 Changes in MABP.
Time Group D N= 35 Group E N= 35 P1
T0 65.54 ± 5.33 62.45 ± 4.52 0.62
T1 68.62 ± 4.25 65.54 ± 4.45 0.74
T2 55.52 ± 3.42 54.45 ± 4.33 0.43
T3 48.45 ± 5.40 46.54 ± 34 0.65
T4 52.54 ± 4.33 54.33 ± 4.42 0.56
T5 55.52 ± 4.32 54.34 ± 3,54 0.53
T0 = baseline, t1 = after intubation, t2 = 5 min after drugs
infusion, t3 = 30 min after drugs infusion, t4 = 60 min after drugs
infusion and t5 = 90 min after drugs infusion.
Table 6 Changes in HR.
Time Group D N= 35 Group E N= 35 P1
T0 127.45 ± 4.82 125.65 ± 5.44 0.64
T1 121.33 ± 5.32 122.48 ± 4,55 0.72
T2 104.32 ± 5.42 106.54 ± 4.23 0.62
T3 89.45 ± 4.32 92.43 ± 4.33 0.73
T4 85.3 ± 5.34 90.53 ± 4,32 0.67
T5 80.24 ± 3.4 85.43 ± 4.34 0.72
T0 = baseline, t1 = after intubation, t2 = 5 min after drugs infu-
sion, t3 = 30 min after drug infusion, t4 = 60 min after drugs
infusion and t5 = 90 min after drugs infusion.
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Our study demonstrated that, both dexmedetomidine and
esmolol were effective in reducing blood pressure, heart rate,
minimizing surgical site bleeding, improving quality of surgical
ﬁeld, better visualization of the surgical ﬁeld, and decreasing
operative time with no reported complications in children
underwent cochlear implant surgery.
Intraoperative goals are to maintain stable hemodynamics,
to provide immobile bloodless ﬁeld, modulation of anesthetic
technique to allow facial nerve monitoring and to reduce inter-
ference with stapedius reﬂex testing. Measures should be taken
to prevent postoperative nausea and vomiting and adequate
analgesia should be provided [12].
Dexmedetomidine is a highly speciﬁc and selective alpha-2-
adrenergic agonist with sedative, anxiolytic, and organ protec-
tive effects. Its clinical applications in children include premed-
ication, prevention of emergence delirium, as part of
multimodal anesthetic regimen and sedation in the pediatric
intensive care unit [13–15].
Dexmedetomidine has anesthetic, analgesic, and sympa-
tholytic properties [16–18]. The sympatholytic effect is mani-
fested by decreases in arterial blood pressure (BP), heart rate
(HR), and norepinephrine release. Thus, dexmedetomidine
has the potential to attenuate perioperative increases in BP
and HR [19,20].
The probable mechanism of reducing blood pressure by
dexmedetomidine is attributed to stimulation of peripheral
alpha2 adrenoceptors of vascular smooth muscle. This results
in decrease in blood pressure and heart rate secondary to inhi-
bition of central sympathetic out ﬂow.A randomized study investigating the effectiveness of
dexmedetomidine in reducing bleeding during septoplasty
and tympanoplasty operations demonstrated dexmedeto-
midine signiﬁcantly reduces bleeding and fentanyl requirement
in septoplasty tympanoplasty operations [15].
Durmus and colleagues [21] used dexmedetomidine to
improve the quality of surgical ﬁeld in both tympanoplasty
and septoplasty, and concluded that dexmedetomidine is a use-
ful adjuvant to decrease bleeding.
Esmolol is an ultra-short acting intravenous cardioselective
beta-antagonist. It has an extremely short elimination half-life
(mean: 9 min; range 4–16 min) and a total body clearance
approaching 3 times of cardiac output and 14 times of hepatic
blood ﬂow [8].
The hypotensive effect of esmolol was a balanced result
between their direct cardiac effect and/or vasomotor effect
and the vasomotor drives originating from the counter-
regulatory responses. Also the hypotensive effect of esmolol
is due to decrease in cardiac output, and the reduction in heart
rate [8].
Esmolol can be administered safely to patients younger
than 6 years after repair of coarctation of the aorta. In the dose
range of 125–500 microg/kg, esmolol signiﬁcantly decreased
systolic blood pressure [22].
Studies [23,24] have shown that induced hypotension with a
beta blocking agent enhanced norepinephrine, endocrine and
metabolic responses of small magnitude during middle ear sur-
gery; this attested that there was an increase of the sympathetic
tone [25,26] leading to vasoconstriction of arterioles andpre-
capillary sphincters that resulted unopposed alpha-adrenergic
effects during esmolol hypotension. However, based on their
known pharmacological effects, beta blockers decrease cardiac
output and therefore decrease the ﬂow to the tissue. However,
beta blockade would only be appropriate for capillary bleeding
[27].
The time to ﬁrst analgesic requirement was shorter in esmo-
lol group and amount of analgesic requirements was less in
dexmedetomidine group.
El Saied MH found that, Dexmedetomidine infusion in
cochlear implantation in pediatric patients was better in induc-
ing deliberate hypotension and providing better quality scale
of surgical ﬁeld compared to fentanyl infusion. It allowed
rapid recovery from anesthesia and reduced need for pain
medication in the PACU [28].
Ibraheim OA et al., found that both esmolol and
dexmedetomidine, added to anesthetic regimen, provided an
effective and well-tolerated method to reduce the amount of
blood loss in patients undergoing scoliosis surgery [29].
Dikmen et al., found that infusion of dexmedetomidine was
effective in inducing consistent and sustained controlled
hypotension, and achieved clear surgical ﬁeld during middle
ear surgery with no need for additional use of a potent
hypotensive agent in low-ﬂow anesthesia. Dexmedetomidine
also reduced isoﬂurane and fentanyl requirements for deliber-
ate hypotension and attenuated cardiovascular responses peri-
operatively [30].
Tobias and Berkenbosch found that, Dexmedetomidine
was an effective agent for controlled hypotension during ante-
rior spinal fusion without the need to use a beta adrenergic
antagonist to control heart rate as is sometimes the case with
direct acting vasodilators [31].
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safely administered to provide hypotensive anesthesia during
middle ear surgery [32].
In line with our ﬁndings, Feld et al. [33] reported that
dexmedetomidine provided stable postoperative analgesia,
thus reducing the use of morphine in the postoperative period
when comparing fentanyl and dexmedetomidine combined
with desﬂurane for bariatric surgery.
Ibraheim et al., found that fentanyl and propofol consump-
tion were signiﬁcantly lower in the dexmedetomidine group
compared with the esmolol and control groups [29].
Unlugenc H, who found that a single i.v. dose of dexmedeto-
midine (1 microg/kg) given 10 min before induction of anesthe-
sia signiﬁcantly reduced postoperative morphine consumption
and had no effect on postoperative recovery time [34].
Dexmedetomidine signiﬁcantly reduces the requirements
for rescue sedation by 80% and analgesia by 50% in postoper-
ative patients for up to 24 h. Its sedative properties differ from
traditional agents with patients being more easily roused [35].
Gurbet et al., found that Continuous iv dexmedetomidine
during abdominal surgery provides effective postoperative
analgesia, and reduces postoperative morphine requirements
without increasing the incidence of side effects [36].
Our study found no signiﬁcant difference between both
groups as regard postoperative nausea and vomiting.
However, Ali et al. [37] reported the incidence of postoper-
ative nausea and vomiting was less in pediatric patients receiv-
ing dexmedetomidine in comparison with those receiving
fentanyl during extracorporeal shock wave lithotripsy. Also,
the same results were reported by Turgut et al. [38] in adult
patients undergoing lumbar laminectomy.
The limitations of the present study, include the following:
no control group, we did not measure the amount of blood
loss, the scale used for assessing the quality of surgical site
bleeding was subjective, and we did not measure the depth
of anesthesia. Further study was needed to compare the
dexmedetomidine with other agent used for controlled
hypotensive anesthesia in children.
5. Conclusion
Our study demonstrated that both dexmedetomidine and
esmolol are safe agents for inducing controlled hypotension
and both are effective in providing ideal surgical ﬁeld in pedi-
atric patients undergoing cochlear implant surgery with no
reported complications. Dexmedetomidine offers the advan-
tage over esmolol and it prolongs postoperative analgesia
and decreases opioid used postoperatively.
Conflict of interest disclosure
Have no conﬂict and No fund.
References
[1] Pedersen CB, Jochumsen U, Madsen S, Koefoed-Nielsen B,
Johansen LV. Results and experiences with 55 cochlear
implantations. Ugeskr Laeger 2000;162(40):5346–50.
[2] Chakrabarty LCA, Tarneja SC, Singh SVA, Roy B, Bhargava
C, Sreevastava LC. Cochlear implant: anaesthesia challenges.
Med J Armed Forces India 2004;60(4):351–6.[3] Aydin GB, Ozlu O, Alacakir H, Aksoy M. Controlled
hypotension: remifentanil or esmolol during tympanoplasty.
Mediterr J Otol 2008;4(2):125–31.
[4] Degoute CS, Ray MJ, Manchon M, Dubreuil C, Banssillon V.
Remifentanil and controlled hypotension; comparison with
nitroprusside or esmolol during tympanoplasty. Can J Anaesth
2001;48(1):20–7.
[5] Brown TCK. Early experiences of vasodilators and hypotensive
anesthesia in children. Pediat Anesthesia 2012;22:720–2.
[6] Ragab SM, Hassanin MZ. Optimizing the surgical . . .ﬁeld in
pediatric functional endoscopic sinus surgery: A new evidence-
based approach. Otolaryngol Head Neck Surg 2010;142
(1):48–54.
[7] Degoute CS. Controlled hypotension: a guide to drug choice.
Drugs 2007;67:1053–76.
[8] Esmolol WiestD. A review of its therapeutic efﬁcacy and
pharmacokinetic characteristics. Clin Pharmacokinet
1995;28:190–202.
[9] Coughlan MG, Lee JG, Bosnjak ZJ, Schemeling WT, Kampine
JP, Warltier DC. Direct coronary and cerebral vascular
responses to dexmedetomidine. Signiﬁcance of endogenous
nitric oxide synthesis. Anesthesiology 1992;77:998–1006.
[10] Dolman RM, Bentley KC, Head TW, English M. The effect of
hypotensive anesthesia on blood loss and operative time during
Le Forte osteotomies. J Oral Maxillofac Surg 2000;58:834–9.
[11] Merkel, Voepel-Lewis. The FLACC: a behavioral scale for
scoring postoperative pain in young children. Pediat Nurs
1997;23:293.
[12] Dalim Kumar Baidya, Maya Dehran. Anaesthesia for cochlear
implant surgery. Trends Anaesth Crit Care 2011;1(2):90–4.
[13] Eber TJ, Hall JE, Bar ney JA, et al. The effects of increasing
plasma concentrations of dexmedetomidine in humans.
Anesthesiology 2000;93(2):382–94.
[14] Talke P, Richardson CA, Scheinin M, Fisher DM.
Postoperative pharmacokinetics and sympatholytic effects of
dexmedetomidine. Anesth Analg 1997;85(5):1136–42.
[15] Ayoglu H, Yapakci O, Ugur MB, Uzun L, Altunkaya H, Ozer
Y, et al. Effectiveness of dexmedetomidine in reducing bleeding
during septoplasty and tympanoplasty operations. J Clin Anesth
2008;20(6):437–41.
[16] Bloor BC, Ward DS, Belleville JP, Maze M. Effects of
intravenous dexmedetomidine in humans. II. Hemodynamic
changes. Anesthesiology 1992;77:1134–42.
[17] Belleville JP, Ward DS, Bloor BC, Maze M. Effects of
intravenous dexmedetomidine in humans. I. Sedation,
ventilation, and metabolic rate. Anesthesiology 1992;77:
1125–33.
[18] Aho M, Lehtinen AM, Erkola O, et al. The effect of
intravenously administered dexmedetomidine on perioperative
hemodynamics and isoﬂurane requirements in patients
undergoing abdominal hysterectomy. Anesthesiology
1991;74:997–1002.
[19] Flacke JW, Bloor BC, Flacke WE, Wong D, Dazza S, Stead SW,
et al. Reduced narcotic requirement by clonidine with improved
hemodynamic and adrenergic stability in patients undergoing
coronary bypass surgery. Anesthesiology 1987;67:11–9.
[20] Roizen MF. Should we all have a sympathectomy at birth? Or at
least preoperatively? Anesthesiology 1988;68:482–4.
[21] Durmus M, But AK, Dogan Z, Yucel A, Miman MC, Ersoy
MO. Effect of dexmedetomidine on bleeding during
tympanoplasty or septorhinoplasty. Eur J Anaesthesiol
2007;24(5):447–53.
[22] Tabbutt S, Nicolson SC, Adamson PC, Zhang X, Hoffman ML,
Wells W, et al. The safety, efﬁcacy, and pharmacokinetics of
esmolol for blood pressure control immediately after repair of
coarctation of the aorta in infants and children: a multicenter,
double-blind, randomized trial. J Thorac Cardiovasc Surg
2008;136(2):321–8.
hypotensive anesthesia and children 261[23] Dietrich GV, Heesen M, Boldt J, Hempelmann G. Platelet
function and adrenoceptors during and after induced
hypotension using nitroprusside. Anesthesiology
1996;85:1334–40.
[24] Blau WS, Kafer ER, Anderson JA. Esmolol is more effective
than sodium nitroprusside in reducing blood loss during
orthognathic surgery. Anesth Analg 1992;75:172–8.
[25] Degoute CS, Dubreuil C, Ray MJ, Guitton J, Manchon M,
Banssillon V, et al. Effects of posture, hypotension and locally
applied vasoconstriction on the middle ear microcirculation in
anaesthetized humans. Eur J Appl Physiol 1994;69:414–20.
[26] Boezaart AP, Van der Merwe J, Coetzee A. Comparison of
sodium nitroprusside and esmolol-induced controlled
hypotension for functional endoscopic sinus surgery. Can J
Anaesth 1995;42:373–6.
[27] Lim YJ, Kim CS, Bahk JH, Ham BM, Do SH. Clinical trial of
esmolol induced controlled hypotension with or without acute
normovolemic hemodilution in spinal surgery. Acta
Anaesthesiol Scand 2003;47:74–8.
[28] El Saied MH, Mohamed NN, Mohamed HM, Amin MI.
Dexmedetomidine versus fentanyl in anesthesia of cochlear
implantation in pediatric patients. Egypt J Anaesth
2016;32:55–9.
[29] Ibraheim OA, Abdulmonem A, Baaj J, Zahrani TA, Arlet V.
Esmolol versus dexmedetomidine in scoliosis surgery: study on
intraoperative blood loss and hemodynamic changes. Middle
East J Anaesthesiol 2013;22(1):27–33.
[30] Dikmen B, Sahin F, Ornek D, Pala Y, Kilci O, Horasanli E,
Canturk M. Dexmedetomidine for controlled hypotension in
middle ear surgery with low-ﬂow anesthesia controlled
hypotension with low-ﬂow anesthesia. Int Adv Otol 2010;6
(3):331–6.[31] Tobias DJ, Berkenbosch WJ. Initial experience with
dexmedetomidine in paediatric-aged patients. Pediat Anaesth
2002;12:171–5.
[32] Nasreen F, Bano S, Khan RM, Hasan SA. Dexmedetomidine
used to provide hypotensive anesthesia during middle ear
surgery. Ind J Otolaryngol Head Neck Surg 2009;61(3):205–7.
[33] Feld JM, Hoffman WE, Stechert MM, Hoffman IW, Ananda
RC. Fentanyl or dexmedetomidine combined with desﬂurane for
bariatric surgery. J Clin Anesth 2006;18(1):24–8.
[34] Unlugenc H, Gunduz M, Guler T, Yagmur O, Isik G. The effect
of pre-anaesthetic administration of intravenous
dexmedetomidine on postoperative pain in patients receiving
patient-controlled morphine. Eur J Anaesthesiol 2005;22
(5):386–91.
[35] Venn RM, Bradshaw CJ, Spencer R, Brealey D, Caudwell E,
Naughton C, et al. Preliminary UK experience of
dexmedetomidine, a novel agent for postoperative sedation in
the intensive care unit. Anaesthesia 1999;54(12):1136–42.
[36] Gurbet A, Basagan-Mogol E, Turker G, Ugun F, Kaya FN,
Ozcan B. Intraoperative infusion of dexmedetomidine reduces
perioperative analgesic requirements. Can J Anaesth 2006;53
(7):646–52.
[37] Ali A, El Ghoneimy M. Dexmedetomidine versus fentanyl as
adjuvant to propofol: comparative study in children undergoing
extracorporeal shock wave lithotripsy. Euro J Anesthesiol
2010;27:1058–64.
[38] Turgut N, Turkmen A, Go¨kkaya S, Altan A, Hatiboglu MA.
Dexmedetomidinebased versus fentanyl-based total intravenous
anesthesia for lumber laminectomy. Minerva Anesthesiol
2008;74:469–74.
